MedGenome, a Bangalore, India-based developer of genomic diagnostics in India and a leading provider of genomics research services globally, raised $20m in Series B funding round.
Backers included Sequoia Capital. In conjunction with the close of the round, Abhay Pandey of Sequoia Capital will join MedGenome’s board of directors,
The company intends to use the funds to further invest in building its bioinformatics infrastructure, enhance its sequencing facilities in India and the US, and expand its research and scientific teams.
Led by CEO Sam Santhosh, MedGenome operates an independent Next Generation Sequencing (NGS) lab and an integrated genomics platform already being used for numerous genomic research projects in areas such as cancer and immunotherapies, metabolic diseases, Parkinson’s disease, kidney, liver, and ophthalmological diseases, diabetes, deafness, and aging. In India,
The company’s clinical diagnostics tests include Natera’s Panorama non-invasive prenatal test (NIPT), which is used by major hospitals to screen for genetic and chromosomal abnormalities during pregnancy.